Passage Bio (PASG)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 4.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.36% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Remix to go public in reverse merger with once high-flying Passage Bio
- PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?
- Passage Bio and Remix Therapeutics Announce Merger Agreement
- Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
- Sector Update: Health Care Stocks Softer Late Afternoon
- Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
- Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
- SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Incidence of dementia and mild cognitive impairment in two Indigenous Bolivian cohorts. — Alzheimers Dement 2026 Sep PMID 42742085
- Desmodium styracifolium Total Flavone Capsules for Urolithiasis: A Phase 3 Randomized Clinical Trial. — JAMA Netw Open 2026 Sep 1 PMID 42714908
- Risk of transmission of amyloid β pathology via transfused blood products. — Lancet 2026 Aug 22 PMID 42624157
- CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults. — Alzheimers Dement 2026 Aug PMID 42583778
- Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. — JAMA Neurol 2026 Sep 1 PMID 42545715
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Passage Bio.
Full PASG Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.